Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects

Healthy subjects have been selected as the study population for this comparative study because this population is more homogenous with respect to immune response and offers significant advantages with regards to recruitment and logistical aspects. This study will comprise of two cycles with each cycles will have a single dose of PEG FILGRASTIM administration to all study subjects as per the randomization schedule. Subjects will be confined from at least 10 hours prior to dosing, at the time indicated by the CRU, until 36 hours post-dose on day 2 in each Cycle. Dosing in each Cycle are separated by 21 days. Subjects will return for all subsequent blood draws and ADA assessments, as indicated in The Schedule of Event